Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation in the United States. Currently-available treatments are characterized by suboptimal tolerability and efficacy, resulting in a high unmet need for therapies that can be used to treat the broader HCV patient population.
This report covers patients’ attitudes, perceptions and behavior regarding their chronic HCV infections and their disease management. With a focus on understanding a patient’s path to diagnosis and the chain of care, this study will provide insight on the physician-patient interaction and relationship. The report will also look at what drives patients’ satisfaction with their current HCV treatment, especially with regards to first-generation protease inhibitor triple therapy, and identify what treatment attributes are most likely to prompt a patient to discontinue treatment or opt to delay treatment until an emerging therapies become available. Further, this study will gauge patient awareness of emerging therapies and patient expectations for treatment effectiveness and tolerability for follow-on therapies.
~250 patients diagnosed with HCV who have seen a gastroenterologist, hepatologist or infectious disease specialist at least once in the past year complete a 45-minute online quantitative survey. In addition, 15 patients participate in a 30-minute qualitative interview.
To qualify, surveyed respondents must meet the following criteria:
- Be between 18 and 80 years of age
- Received a diagnosis of HCV (limited to genotype 1, 2 and 3) from a physicians and have seen a gastroenterologist, hepatologist, or infectious disease specialist at least once in the past year
- No current participation in any clinical trials for HCV
- No members of household working for an advertising agency, market research company or a company that makes or distributes pharmaceutical drugs
- Publish: August 2013
- 250 Hepatitis C patients are surveyed and 15 patients are interviewed
- United States
Key Drugs Covered:
- Incivek (telaprevir), Victrelis (boceprevir), Pegasys (peg-IFN-?-2a), PegIntron (peg-IFN-?-2b ), and ribavirin, and products in late-stage development, including ABT-267, ABT-333, ABT-450, BI-207127, asunaprevir, daclatasvir, faldaprevir, ledipasvir simeprevir and sofosbuvir
Key Comapnaies Mentioned:
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Johnson & Johnson / Janssen
- Final report in powerpoint format
- Complete set of frequency tables, summary statistics and cross tabulations can be provided upon request
- Transcripts from qualitative interviews can be provided upon request
- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions.
Related Reports and Products:
- TreatmentTrends®: Hepatitis C Virus (US)
- TreatmentTrends®: Hepatitis C Virus (EU)
- ChartTrends®: Hepatitis C Virus (US)
- LaunchTrends®: Sofosbuvir and Simeprevir (US)
- Pharmacor®: Hepatitis C Virus
- DecisionBase®: Treatment-Naïve Hepatitis C Virus p>
- Physician and Payer Forum (EU)®: The Impending Interferon-Free Era of Hepatitis C Virus Treatment
- Emerging Markets®: Hepatitis C Virus in Turkey
- Physician and Payer Forum Emerging Markets®: Hepatitis C Virus in Brazil, Mexico, and Argentina